RGC
Price
$13.01
Change
+$0.67 (+5.43%)
Updated
Dec 3 closing price
Capitalization
6.43B
Intraday BUY SELL Signals
SUPN
Price
$44.76
Change
+$0.64 (+1.45%)
Updated
Dec 3 closing price
Capitalization
2.57B
89 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

RGC vs SUPN

Header iconRGC vs SUPN Comparison
Open Charts RGC vs SUPNBanner chart's image
Regencell Bioscience Holdings
Price$13.01
Change+$0.67 (+5.43%)
Volume$245.73K
Capitalization6.43B
Supernus Pharmaceuticals
Price$44.76
Change+$0.64 (+1.45%)
Volume$527.46K
Capitalization2.57B
RGC vs SUPN Comparison Chart in %
RGC
Daily Signal:
Gain/Loss:
SUPN
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
RGC vs. SUPN commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RGC is a Hold and SUPN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (RGC: $12.44 vs. SUPN: $44.15)
Brand notoriety: RGC and SUPN are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: RGC: 122% vs. SUPN: 19%
Market capitalization -- RGC: $6.43B vs. SUPN: $2.57B
RGC [@Pharmaceuticals: Generic] is valued at $6.43B. SUPN’s [@Pharmaceuticals: Generic] market capitalization is $2.57B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RGC’s FA Score shows that 0 FA rating(s) are green whileSUPN’s FA Score has 0 green FA rating(s).

  • RGC’s FA Score: 0 green, 5 red.
  • SUPN’s FA Score: 0 green, 5 red.
According to our system of comparison, SUPN is a better buy in the long-term than RGC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RGC’s TA Score shows that 4 TA indicator(s) are bullish while SUPN’s TA Score has 5 bullish TA indicator(s).

  • RGC’s TA Score: 4 bullish, 5 bearish.
  • SUPN’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, SUPN is a better buy in the short-term than RGC.

Price Growth

RGC (@Pharmaceuticals: Generic) experienced а +10.24% price change this week, while SUPN (@Pharmaceuticals: Generic) price change was -4.19% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.67%. For the same industry, the average monthly price growth was +0.42%, and the average quarterly price growth was +25.91%.

Reported Earning Dates

SUPN is expected to report earnings on Mar 03, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+3.67% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGC($6.43B) has a higher market cap than SUPN($2.57B). RGC YTD gains are higher at: 9465.309 vs. SUPN (22.096). SUPN has higher annual earnings (EBITDA): 174M vs. RGC (-3.99M). SUPN has more cash in the bank: 523M vs. RGC (2.96M). RGC has less debt than SUPN: RGC (85.7K) vs SUPN (31.8M). SUPN has higher revenues than RGC: SUPN (665M) vs RGC (0).
RGCSUPNRGC / SUPN
Capitalization6.43B2.57B251%
EBITDA-3.99M174M-2%
Gain YTD9465.30922.09642,837%
P/E RatioN/A49.57-
Revenue0665M-
Total Cash2.96M523M1%
Total Debt85.7K31.8M0%
FUNDAMENTALS RATINGS
RGC vs SUPN: Fundamental Ratings
RGC
SUPN
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
78
Overvalued
PROFIT vs RISK RATING
1..100
10034
SMR RATING
1..100
10080
PRICE GROWTH RATING
1..100
3453
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
3565

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SUPN's Valuation (78) in the Pharmaceuticals Other industry is in the same range as RGC (96) in the Movies Or Entertainment industry. This means that SUPN’s stock grew similarly to RGC’s over the last 12 months.

SUPN's Profit vs Risk Rating (34) in the Pharmaceuticals Other industry is significantly better than the same rating for RGC (100) in the Movies Or Entertainment industry. This means that SUPN’s stock grew significantly faster than RGC’s over the last 12 months.

SUPN's SMR Rating (80) in the Pharmaceuticals Other industry is in the same range as RGC (100) in the Movies Or Entertainment industry. This means that SUPN’s stock grew similarly to RGC’s over the last 12 months.

RGC's Price Growth Rating (34) in the Movies Or Entertainment industry is in the same range as SUPN (53) in the Pharmaceuticals Other industry. This means that RGC’s stock grew similarly to SUPN’s over the last 12 months.

RGC's P/E Growth Rating (100) in the Movies Or Entertainment industry is in the same range as SUPN (100) in the Pharmaceuticals Other industry. This means that RGC’s stock grew similarly to SUPN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RGCSUPN
RSI
ODDS (%)
Bullish Trend 7 days ago
77%
Bearish Trend 7 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 7 days ago
87%
Bullish Trend 7 days ago
81%
Momentum
ODDS (%)
Bearish Trend 7 days ago
90%
Bullish Trend 7 days ago
80%
MACD
ODDS (%)
N/A
Bearish Trend 7 days ago
74%
TrendWeek
ODDS (%)
Bearish Trend 7 days ago
89%
Bullish Trend 7 days ago
74%
TrendMonth
ODDS (%)
Bearish Trend 7 days ago
89%
Bearish Trend 7 days ago
65%
Advances
ODDS (%)
Bullish Trend 17 days ago
85%
Bullish Trend 9 days ago
76%
Declines
ODDS (%)
Bearish Trend 9 days ago
89%
Bearish Trend 22 days ago
62%
BollingerBands
ODDS (%)
Bullish Trend 7 days ago
87%
Bullish Trend 7 days ago
80%
Aroon
ODDS (%)
Bearish Trend 7 days ago
89%
Bullish Trend 7 days ago
65%
View a ticker or compare two or three
Interact to see
Advertisement
RGC
Daily Signal:
Gain/Loss:
SUPN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MADVX21.65N/A
N/A
BlackRock Equity Dividend Instl
SECIX50.27N/A
N/A
NAA Large Cap Value A
SESLX34.01N/A
N/A
1919 Socially Responsive Balanced C
TIOTX17.29N/A
N/A
Nuveen International Opps Retire
AFOZX20.84N/A
N/A
Alger Mid Cap Focus Z

RGC and

Correlation & Price change

A.I.dvisor tells us that RGC and QNTM have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RGC and QNTM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGC
1D Price
Change %
RGC100%
+4.06%
QNTM - RGC
21%
Poorly correlated
+14.94%
SBFM - RGC
20%
Poorly correlated
+5.01%
CPHI - RGC
13%
Poorly correlated
+5.52%
ANIP - RGC
11%
Poorly correlated
-2.72%
SUPN - RGC
7%
Poorly correlated
-1.23%
More

SUPN and

Correlation & Price change

A.I.dvisor tells us that SUPN and PRGO have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SUPN and PRGO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SUPN
1D Price
Change %
SUPN100%
-1.23%
PRGO - SUPN
31%
Poorly correlated
-1.59%
SNDL - SUPN
27%
Poorly correlated
+1.79%
ACET - SUPN
27%
Poorly correlated
-8.24%
SILFF - SUPN
27%
Poorly correlated
N/A
ESPR - SUPN
26%
Poorly correlated
-1.61%
More